When IL‐17 inhibitors fail: Real‐life evidence to switch from secukinumab to adalimumab or ustekinumab
- 5 December 2018
- journal article
- research article
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (2) , e12793
Abstract
Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL‐12/23 and IL‐17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL‐12/23 and TNF inhibitors to IL‐17 inhibitors, conversely nothing is present toward the switch from IL‐17 inhibitors to IL‐12/23 and TNF inhibitors. We performed a real‐life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL‐12/23 inhibitor. Our observational study suggests that switching from IL‐17i to TNFi and IL‐12/23i is a safe and effective therapeutic strategy.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50 AR 070590 01A1)
This publication has 15 references indexed in Scilit:
- Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective studyJournal of the American Academy of Dermatology, 2018
- Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agentsWorld Journal of Hepatology, 2018
- Liver Illness and Psoriatic PatientsBioMed Research International, 2018
- A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque PsoriasisClinical Drug Investigation, 2017
- Switching of biologics in psoriasis: Reasons and resultsThe Journal of Dermatology, 2017
- A systematic review of worldwide epidemiology of psoriasisJournal of the European Academy of Dermatology and Venereology, 2016
- An evolution in switching therapy for psoriasis patients who fail to meet treatment goalsDermatologic Therapy, 2015
- The economic burden of psoriasis: a systematic literature reviewExpert Review of Pharmacoeconomics & Outcomes Research, 2014
- Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare RegistryJournal of the American Academy of Dermatology, 2014
- Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD studyAnnals of the Rheumatic Diseases, 2013